Avidity Biosciences Inc Stock News

SAN DIEGO , Sept. 15, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has closed its previously announced underwritten public offering of 17,250,000 shares of its common stock, including 2,250,000 shares sold pursuant to th...

SAN DIEGO , Sept. 11, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of its upsized underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $40.00 per share.

Avidity Biosciences remains a Strong Buy for me, driven by Del-zota's promising data in targeting Duchenne Muscular Dystrophy exon 44 skipping patients. Del-zota showed sustained 25% dystrophin production and 80% CK reduction over 16 months, with functional improvements versus natural history. A BLA filing for Del-zota under Accelerated Approval is expected by year-end 2025, with additional dat...

Avidity Biosciences, Inc. (NASDAQ:RNA ) Discusses on Redefining the Treatment of Duchenne Muscular Dystrophy Conference Call September 10, 2025 8:00 AM EDT Company Participants Katja Lange - Senior VP & Chief Business Officer Sarah Boyce - President, CEO & Director Steven Hughes - Chief Medical Officer W. Flanagan - Chief Scientific Officer Presentation Katja Lange Senior VP & Chief Business Of...

SAN DIEGO , Sept. 10, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $500.0 million of shares of its common stock in an underwritten public offering.

-- Unprecedented improvement compared to baseline and natural history in multiple functional measures including Time to Rise from Floor (TTR), 4-Stair Climb (4SC), Performance of Upper Limb (PUL) and 10-Meter Walk/Run Test (10mWRT) at approximately one year -- -- Unprecedented rapid reduction in creatine kinase (CK) to near normal levels maintained over 16 months of follow-up and 25% increase o...

Avidity Biosciences, Inc. (NASDAQ:RNA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:50 PM EDT Company Participants Kathleen Gallagher - Chief Program Officer Michael MacLean - Chief Financial Officer Katja Lange - Senior VP & Chief Business Officer Presentation Unknown Analyst Good afternoon. Thank you for coming to the Morgan Stanley Healthcare Conference.

Avidity Biosciences, Inc. (NASDAQ:RNA ) Cantor Global Healthcare Conference 2025 September 3, 2025 10:20 AM EDT Company Participants Sarah Boyce - President, CEO & Director Steven Hughes - Chief Medical Officer Conference Call Participants Eric Schmidt - Cantor Fitzgerald & Co., Research Division Presentation Eric Schmidt Research Analyst Okay. Good morning once again, everyone.